COVID-19 in haematology patients: A multi-centre West Midlands clinical outcomes analysis on behalf of West Midlands Research Consortium

Hana Morrissey; Patrick Ball; Anandadeep Mandal; Alan Nevill; Shankara Paneesha; Supratik Basu; Farheen Karim; Mohammed Imran; Neil Phillips; Jahanzeb Khawaja; Jackie Stone; Duncan Murray; Katie Randall; Vidhya Murthy; Bhuvan Kishore; Manos Nikolousis; Guy Pratt; Jeff Neilson; Nick Pemberton; Farooq Wandroo

doi:10.1111/bjh.17136

COVID-19 in haematology patients: A multi-centre West Midlands clinical outcomes analysis on behalf of West Midlands Research Consortium

Hana Morrissey, Patrick Ball, Anandadeep Mandal, Alan Nevill, Shankara Paneesha, Supratik Basu, Farheen Karim, Mohammed Imran, Neil Phillips, Jahanzeb Khawaja, Jackie Stone, Duncan Murray, Katie Randall, Vidhya Murthy, Bhuvan Kishore, Manos Nikolousis, Guy Pratt, Jeff Neilson, Nick Pemberton, Farooq Wandroo

Nursing, Paramedicine and Healthcare Sciences

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

Since COVID‐19 first appeared it has been clear that whilst many patients experience relatively minor symptoms, some develop a more serious disease. Studies have suggested that oncology patients, including those with haematological malignancies, have a greater risk of severe COVID‐19 disease with increased morbidity and mortality. This retrospective study, conducted by clinicians and researchers from nine West Midlands hospitals, included all adult patients with both an underlying haematological disorder and confirmed COVID‐19, diagnosed between 1st March and 31st May 2020. Demographic, clinical, laboratory, radiological and outcome data were collected using a standardised form. COVID‐19 was diagnosed by reverse transcription‐polymerase chain reaction. An ethical clearance waiver for the audit was received from the nine hospitals involved.

Original language	English
Pages (from-to)	e11-e14
Number of pages	4
Journal	British Journal of Haematology
DOIs	https://doi.org/10.1111/bjh.17136
Publication status	Published - 05 Nov 2021

Access to Document

10.1111/bjh.17136

http://hdl.handle.net/2436/623656

Cite this

Morrissey, H., Ball, P., Mandal, A., Nevill, A., Paneesha, S., Basu, S., Karim, F., Imran, M., Phillips, N., Khawaja, J., Stone, J., Murray, D., Randall, K., Murthy, V., Kishore, B., Nikolousis, M., Pratt, G., Neilson, J., Pemberton, N., & Wandroo, F. (2021). COVID-19 in haematology patients: A multi-centre West Midlands clinical outcomes analysis on behalf of West Midlands Research Consortium. British Journal of Haematology, e11-e14. https://doi.org/10.1111/bjh.17136

@article{af561249d719489bbfc5422ddcc12484,

title = "COVID-19 in haematology patients: A multi-centre West Midlands clinical outcomes analysis on behalf of West Midlands Research Consortium",

abstract = "Since COVID‐19 first appeared it has been clear that whilst many patients experience relatively minor symptoms, some develop a more serious disease. Studies have suggested that oncology patients, including those with haematological malignancies, have a greater risk of severe COVID‐19 disease with increased morbidity and mortality. This retrospective study, conducted by clinicians and researchers from nine West Midlands hospitals, included all adult patients with both an underlying haematological disorder and confirmed COVID‐19, diagnosed between 1st March and 31st May 2020. Demographic, clinical, laboratory, radiological and outcome data were collected using a standardised form. COVID‐19 was diagnosed by reverse transcription‐polymerase chain reaction. An ethical clearance waiver for the audit was received from the nine hospitals involved.",

keywords = "COVID-19, Haematological Conditions, Haematology patients, Lung infiltrates, SARS-Cov-2",

author = "Hana Morrissey and Patrick Ball and Anandadeep Mandal and Alan Nevill and Shankara Paneesha and Supratik Basu and Farheen Karim and Mohammed Imran and Neil Phillips and Jahanzeb Khawaja and Jackie Stone and Duncan Murray and Katie Randall and Vidhya Murthy and Bhuvan Kishore and Manos Nikolousis and Guy Pratt and Jeff Neilson and Nick Pemberton and Farooq Wandroo",

year = "2021",

month = nov,

day = "5",

doi = "10.1111/bjh.17136",

language = "English",

pages = "e11--e14",

journal = "British Journal of Haematology",

issn = "1365-2141",

publisher = "Wiley-Blackwell",

}

Morrissey, H, Ball, P, Mandal, A, Nevill, A, Paneesha, S, Basu, S, Karim, F, Imran, M, Phillips, N, Khawaja, J, Stone, J, Murray, D, Randall, K, Murthy, V, Kishore, B, Nikolousis, M, Pratt, G, Neilson, J, Pemberton, N & Wandroo, F 2021, 'COVID-19 in haematology patients: A multi-centre West Midlands clinical outcomes analysis on behalf of West Midlands Research Consortium', British Journal of Haematology, pp. e11-e14. https://doi.org/10.1111/bjh.17136

TY - JOUR

T1 - COVID-19 in haematology patients

T2 - A multi-centre West Midlands clinical outcomes analysis on behalf of West Midlands Research Consortium

AU - Morrissey, Hana

AU - Ball, Patrick

AU - Mandal, Anandadeep

AU - Nevill, Alan

AU - Paneesha, Shankara

AU - Basu, Supratik

AU - Karim, Farheen

AU - Imran, Mohammed

AU - Phillips, Neil

AU - Khawaja, Jahanzeb

AU - Stone, Jackie

AU - Murray, Duncan

AU - Randall, Katie

AU - Murthy, Vidhya

AU - Kishore, Bhuvan

AU - Nikolousis, Manos

AU - Pratt, Guy

AU - Neilson, Jeff

AU - Pemberton, Nick

AU - Wandroo, Farooq

PY - 2021/11/5

Y1 - 2021/11/5

N2 - Since COVID‐19 first appeared it has been clear that whilst many patients experience relatively minor symptoms, some develop a more serious disease. Studies have suggested that oncology patients, including those with haematological malignancies, have a greater risk of severe COVID‐19 disease with increased morbidity and mortality. This retrospective study, conducted by clinicians and researchers from nine West Midlands hospitals, included all adult patients with both an underlying haematological disorder and confirmed COVID‐19, diagnosed between 1st March and 31st May 2020. Demographic, clinical, laboratory, radiological and outcome data were collected using a standardised form. COVID‐19 was diagnosed by reverse transcription‐polymerase chain reaction. An ethical clearance waiver for the audit was received from the nine hospitals involved.

AB - Since COVID‐19 first appeared it has been clear that whilst many patients experience relatively minor symptoms, some develop a more serious disease. Studies have suggested that oncology patients, including those with haematological malignancies, have a greater risk of severe COVID‐19 disease with increased morbidity and mortality. This retrospective study, conducted by clinicians and researchers from nine West Midlands hospitals, included all adult patients with both an underlying haematological disorder and confirmed COVID‐19, diagnosed between 1st March and 31st May 2020. Demographic, clinical, laboratory, radiological and outcome data were collected using a standardised form. COVID‐19 was diagnosed by reverse transcription‐polymerase chain reaction. An ethical clearance waiver for the audit was received from the nine hospitals involved.

KW - COVID-19

KW - Haematological Conditions

KW - Haematology patients

KW - Lung infiltrates

KW - SARS-Cov-2

U2 - 10.1111/bjh.17136

DO - 10.1111/bjh.17136

M3 - Article

C2 - 33151540

SN - 1365-2141

SP - e11-e14

JO - British Journal of Haematology

JF - British Journal of Haematology

ER -

COVID-19 in haematology patients: A multi-centre West Midlands clinical outcomes analysis on behalf of West Midlands Research Consortium

Abstract

Access to Document

Fingerprint

Cite this